Home | Medical Need | R&D Programmes | Company | Collaborations | News |

Northern Antibiotics fights against multi-resistant Gram-negatives
Northern Antibiotics has developed two series of novel compounds that are highly active against difficult-to-treat Gram-negative bacteria such as multi-resistant Escherichia coli, Klebsiella pneumoniae, other species of Enterobacteriaceae, and Acinetobacter baumannii.

The first series is directly antibacterial and includes a compound with a remarkable activity against Pseudomonas aeruginosa, too. The second series sensitizes Gram-negative enteric bacteria and Acinetobacter by more than 100 times to the action of antibiotics usually used for the treatment of Gram-positive infections only.

The lead compounds of both series are in late preclinical development. The results from both in vitro and in vivo studies indicate the desired efficacy and safety profile.

Northern Antibiotics has filed both U.S. and Patent cooperation Treaty (PCT) patent applications claiming composition-of-matter, pharmaceutical compositions and therapeutic uses of the compounds.

For more information, click the link below.
Novel Polymyxins for the treatment of serious Gram-negative hospital infections
  Northern Antibiotics Ltd
Tekniikantie 14 (Technopolis, Innopoli 2) Suite A111, FIN-02150 Espoo, Finland
Phone: +358-50-355 0822
E-mail: admin@northernantibiotics.com
  Copyright © 2007-2018 Northern Antibiotics Ltd